Bausch Says Potential Sale of Bausch + Lomb Still On Table

Dow Jones12-12

By Dean Seal

Bausch Health said a potential sale of its subsidiary Bausch + Lomb is still on the table following a report that one suitor might back out of a joint bid to acquire the eye-health company.

The Canadian pharmaceutical company said Thursday that it was confirming the potential sale process at the behest of Canadian regulators in light of recent stock volatility related to market rumors.

Bausch seemed to be referencing a report from the Financial Times on Wednesday that Blackstone was balking at the high price being sought for Bausch + Lomb. It previously teamed up with investor TPG to explore a bid for the subsidiary company, of which Bausch owns 88%.

Bausch said it still believes a full separation of the subsidiary "makes strategic sense" and that a potential sale is one of several options being considered.

"No decision has been reached to proceed with any particular transaction, and there can be no assurance that it will result in a transaction," the company said.

In October, Bausch rejected debt-restructuring proposals from bondholders aimed at staving off bankruptcy and pivoted to exploring a sale of its Bausch + Lomb stake that could pay off creditors and reward shareholders, according to a report from The Wall Street Journal.

Bausch faces more than $11 billion in debt maturities by 2028. Around that time, it will lose its patent on the gastrointestinal drug Xifaxan.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

December 12, 2024 08:05 ET (13:05 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490388224?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-12 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490388224","market":"other","top_or_hot":-1,"title":"Bausch Says Potential Sale of Bausch + Lomb Still On Table","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  Bausch Health said a potential sale of its subsidiary Bausch + Lomb is still on the table following a report that one suitor might back out of a joint bid to acquire the eye-health company. \n</p>\n<p>\n  The Canadian pharmaceutical company said Thursday that it was confirming the potential sale process at the behest of Canadian regulators in light of recent stock volatility related to market rumors. \n</p>\n<p>\n  Bausch seemed to be referencing a report from the Financial Times on Wednesday that Blackstone was balking at the high price being sought for Bausch + Lomb. It previously teamed up with investor TPG to explore a bid for the subsidiary company, of which Bausch owns 88%. \n</p>\n<p>\n  Bausch said it still believes a full separation of the subsidiary \"makes strategic sense\" and that a potential sale is one of several options being considered. \n</p>\n<p>\n  \"No decision has been reached to proceed with any particular transaction, and there can be no assurance that it will result in a transaction,\" the company said. \n</p>\n<p>\n  In October, Bausch rejected debt-restructuring proposals from bondholders aimed at staving off bankruptcy and pivoted to exploring a sale of its Bausch + Lomb stake that could pay off creditors and reward shareholders, according to a report from The Wall Street Journal. \n</p>\n<p>\n  Bausch faces more than $11 billion in debt maturities by 2028. Around that time, it will lose its patent on the gastrointestinal drug Xifaxan. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 12, 2024 08:05 ET (13:05 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bausch Says Potential Sale of Bausch + Lomb Still On Table</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBausch Says Potential Sale of Bausch + Lomb Still On Table\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-12 21:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Dean Seal \n\n\n \n\n\n  Bausch Health said a potential sale of its subsidiary Bausch + Lomb is still on the table following a report that one suitor might back out of a joint bid to acquire the eye-...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BHC","symbol_name":"Bausch Health Companies Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2490388224","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490388224","pubTimestamp":1734008700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Bausch Health said a potential sale of its subsidiary Bausch + Lomb is still on the table following a report that one suitor might back out of a joint bid to acquire the eye-health company.The Canadian pharmaceutical company said Thursday that it was confirming the potential sale process at the behest of Canadian regulators in light of recent stock volatility related to market rumors.Bausch seemed to be referencing a report from the Financial Times on Wednesday that Blackstone was balking at the high price being sought for Bausch + Lomb. It previously teamed up with investor TPG to explore a bid for the subsidiary company, of which Bausch owns 88%.Bausch said it still believes a full separation of the subsidiary \"makes strategic sense\" and that a potential sale is one of several options being considered.In October, Bausch rejected debt-restructuring proposals from bondholders aimed at staving off bankruptcy and pivoted to exploring a sale of its Bausch + Lomb stake that could pay off c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BHC":"Bausch Health Companies Inc","BK4007":"制药"},"translate_title":"博士伦表示出售博士伦的可能性仍在讨论中","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHC":0.9},"content_text":"By Dean Seal \n\n\n \n\n\n  Bausch Health said a potential sale of its subsidiary Bausch + Lomb is still on the table following a report that one suitor might back out of a joint bid to acquire the eye-health company. \n\n\n  The Canadian pharmaceutical company said Thursday that it was confirming the potential sale process at the behest of Canadian regulators in light of recent stock volatility related to market rumors. \n\n\n  Bausch seemed to be referencing a report from the Financial Times on Wednesday that Blackstone was balking at the high price being sought for Bausch + Lomb. It previously teamed up with investor TPG to explore a bid for the subsidiary company, of which Bausch owns 88%. \n\n\n  Bausch said it still believes a full separation of the subsidiary \"makes strategic sense\" and that a potential sale is one of several options being considered. \n\n\n  \"No decision has been reached to proceed with any particular transaction, and there can be no assurance that it will result in a transaction,\" the company said. \n\n\n  In October, Bausch rejected debt-restructuring proposals from bondholders aimed at staving off bankruptcy and pivoted to exploring a sale of its Bausch + Lomb stake that could pay off creditors and reward shareholders, according to a report from The Wall Street Journal. \n\n\n  Bausch faces more than $11 billion in debt maturities by 2028. Around that time, it will lose its patent on the gastrointestinal drug Xifaxan. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2024 08:05 ET (13:05 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490388224"}